Olivia Cavlan, MD
Dr. Cavlan is a biotech builder and former clinician scientist. She joined Alchemab as founding Head of Business having been an Investment Principal at SV Health Investors. Previously, Dr. Cavlan was a Partner with McKinsey & Company where she was part of the leadership team in the Healthcare Private Equity and Pharmaceutical practices. While at McKinsey, Dr. Cavlan co-led the global Real World Evidence practice and QuantumBlack biopharmaceutical offering where she led work on target discovery and clinical development. She has also led several global biopharma R&D transformation efforts and developed clinical and commercial strategies for a number of preclinical assets.
Dr. Cavlan is a Non-Executive Director for the UK BioIndustry Association and a member of the Investment Committee for Cancer Research UK’s (CRUK) Seed fund. She also co-founded and sits on the Board of Directors of Sevenless Therapeutics, a small molecule pain company.
Dr. Cavlan holds an MBChB in Medicine and a BSc in Pharmacology from Bristol University where she graduated with the top First Class Honours.